Memorable eve at the Lachlan Kean Foundation Ball raising awareness for early onset colorectal cancer @GarvanInstitute@kinghorncancer @GICancer
Bowel cancer screening now starts age 45 or 40 if you ask your GP. Pay attention to symptoms at any age - this disease is changing
@gjmccaughan @SVHSydney @kinghorncancer@annabelcrabb Great night raising awareness for early onset colorectal cancer and valuable funds for research with @GICancer !
TOPAZ-1 update at mFU 41m - OS HR strengthened 0.8 —> 0.74, if have a CR/PR 1/3 alive at 3y vs 16% chemo. 17% ‘long term’ survivors, across all subgroups iCCA/eCCA/GBC/ROW/PDL1 #ESMOGI24
Promising ORR 32% in CLDN18.2 mod/high (90% cohort) heavily pre treated pt w/ G/GOJ. Similar responses, less N/V than other CLDN18.2 Abs @JiaJennyLiu@kinghorncancer#ESMOGI24
@MacarullaTeresa presenting 18m update CD40a mitazalimab + mFFX in metPDAC. ORR 42%, med DoR 12.6m(!), 1y PFS 55%. Compares well w FFX ORR 31% 1y PFS 12%. Mita added minimal liver tox / no CRS. Progressing to Ph3 #ESMOGI24
Biological rationale of EGFR-MET Bispec Ab Amivantamab w/ @TaberneroJosep; averting met-amplification rel. resistance, inducing ADCC. We will test in 1L Ph3 ORIGAMI-2 trial w/ platinum doublet vs CT/cetux in RAS/BRAFwt L-sided mCRC opening soon👊 @kinghorncancer#ESMOGI24
PDAC has more negative trials than any other tumour stream… Trying to find Prof Thomas Seufferlein’s summary slide motivating rather than deflating.
Nal-iri combos underwhelming and not compared to FOLFIRI/mFFX
#ESMOGI24
Laurence Zitvogel @GustaveRoussy tour de force microbiome. Meta-anal. AB use -60 to +42d C1 PD1; surge pathogenic bact. post AB down-reg gut checkpoint MadCAM —> exodus immunosupp cells inc Th17 from gut to cancer. PD1 at this point amplifies exodus 🪨/doc/hard place #ESMOGI24
Thought provoking talk from @ben_irit on QoL issues in EOCRC, esp paucity of data re: fertility pres. w/ RT + oxali (can’t extrapolate GnRHa from CTX - can worsen problem), cardiovascular tox (CVD 54% CRC survivors v 17% Gen pop), psychosocial, body image, sexual fnc #ESMOGI24
Unsurprising QoL data for TRANSMET, late deviation in favour LT+C v C. Interesting summary from @ChiaraCrem1 re pattern of relapse liver TP (lung dominant) v resection (liver dominant) #ESMOGI24
RV of rationale for differing OS + ongoing pref up-front surgery Asian v Western gastric w/ Prof Sun Young Rha @yonsei_u: 5yOS >60 v 25% ! Screening program/more early disease, long-standing D2 dissection SoC, diff histo path (non-cardia > cardia). #ESMOGI24
Masterclass in ctDNA from @JeanneTie at #ESMOGI24. Efforts to improve sensitivity inc: track more muts (WES vs panel), reduce BG noise (seq PBMCs, technical improvements), increase cf DNA input (how much blood ethically ok w serial collections) #aussiesonthepodium
Great summary from Ryan Corcoran @MGHCancerCenter re targeting RAS. Similar single agent ORR G12Cinh PDAC compared w/ NSCLC, vs CRC which improves w/ addition anti-EGFR. Supports KRAS good target in PDAC …just need to progress in G12D #ESMOGI24